H Jules & Company Limited, is committed to the research and development field by advancements in drug delivery technologies and solutions. The company’s mission is to strive continuously for improvement in patient outcomes and address evolving pharmaceutical needs. A glimpse of some ongoing research initiatives in synthetic polymer with specific targeting is: focusing particularly on the enhancement of bioavailability, site-specific release, targeted release mucoadhesive release, sustained release, and targeted release.

The E100 product focuses on developing a novel excipient specifically designed to enhance the bioavailability of poorly soluble drugs. This innovative material it utilizes advanced formulation techniques to overcome challenges associated with absorption, and bioavailability potentially leading to more effective treatments. These polymers are also used for transdermal drug delivery.

The RL Series is a range of sustained-release polymers. These polymers offer potential extended drug release profiles, reducing frequent administration and improving patient compliance with medication.

The RS Series explores novel polymers specifically formulated to enhance the stability and safety of sensitive drug molecules. These polymers may offer protection from degradation during storage and transit, ensuring the efficacy and safety of the final drug product.

The EPO project deals with the development of a next-generation platform for EPO as a controlled release carrier for gastro retentive delivery. This technology aims to tailor drug release rates based on individual patient needs, potentially leading to more targeted and effective therapies.

The FS Series targeted to the development of functionalized surfaces for drug delivery systems. These advanced surfaces can be engineered with specific properties to control drug release, improve targeting, or enhance patient compliance with the medication. It’s a flexible functional delayed-release polymer for colon delivery and increased solubility of poorly soluble drugs.

These ongoing research projects represent a few of H Jules & Company’s commitment to pharmaceutical innovation. The company is constantly exploring new frontiers in pharmaceutical technology, focusing on areas such as taste-masking solutions, targeted drug delivery systems for specific organs or tissues, and biocompatible materials for implantable drug delivery devices.

Our dedication to R&D ensures that H Jules & Company Limited remains at the forefront of the pharmaceutical industry, providing cutting-edge solutions that benefit patients worldwide.

You are invited to stay connected with H Jules & Company for future updates on our ongoing research and development initiatives. The company is always excited to share the latest advancements in drug delivery technology as they unfold.